Versant Capital Management
BEAM icon

Versant Capital Management’s Beam Therapeutics BEAM Stock Holding History

Versant Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$30.3K Buy
1,239
+685
+124% +$19.1K ﹤0.01% 1733
2026
Q2 		$19K Sell
554
-8
-1% -$242 ﹤0.01% 1955
2026
Q1 		$13.4K Buy
562
+362
+181% +$10K ﹤0.01% 2010
2025
Q4 		$5.54K Hold
200
– – ﹤0.01% 2220
2025
Q3 		$4.85K Hold
200
– – ﹤0.01% 2217
2025
Q2 		$3.4K Sell
200
-497
-71% -$8.66K ﹤0.01% 2282
2025
Q1 		$13.6K Buy
697
+5
+0.7% +$131 ﹤0.01% 1558
2024
Q4 		$17.2K Buy
692
+195
+39% +$4.98K ﹤0.01% 1110
2024
Q3 		$12.2K Buy
497
+433
+677% +$11.2K ﹤0.01% 991
2024
Q2 		$1.5K Buy
+64
New +$1.57K ﹤0.01% 1581
2023
Q4 		– Sell
-7
Closed -$168 – 1925
2023
Q3 		$168 Sell
7
-98
-93% -$2.63K ﹤0.01% 1892
2023
Q2 		$3.35K Buy
+105
New +$3.41K ﹤0.01% 1177

Other funds holding BEAM

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
D.A. Davidson & Co
D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Versant Capital Management's BEAM Position: Q3 2026 in Review

Versant Capital Management increased its Beam Therapeutics (BEAM) stake by 124% in Q3 2026, buying an estimated $19.1K and bringing the position to 1,239 shares worth $30.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1733.

Versant Capital Management first reported a position in BEAM in Q2 2023 and has held it in 12 quarters since. 96 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • Versant Capital Management held 1,239 shares of Beam Therapeutics worth $30.3K as of Q3 2026.
  • Versant Capital Management bought 685 Beam Therapeutics shares in Q3 2026, an estimated $19.1K.
  • Beam Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1733 holding.
  • Versant Capital Management first reported a position in Beam Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 96 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.